Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
2023年6月22日 - 10:53PM
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”,
“Company”, “We” or “Us”), today announced that effective today,
Edward J. Borkowski, former Chief Financial Officer of Mylan N.V,
has been appointed to the Company’s Board of Directors. Mr.
Borkowski brings significant leadership in capital markets,
finance, accounting, strategy, and mergers & acquisitions to
Nexcella.
After joining Mylan in 2002, Mr. Borkowski held positions of
increasing responsibility including Chief Financial Officer and
Executive Vice President from 2002 until 2009. In addition to his
experience at Mylan, Mr. Borkowski was the former Chief Financial
Officer of CareFusion, where he led the IPO. CareFusion was
ultimately acquired by Becton Dickinson for $12.2 billion.
“We are thrilled to have Mr. Borkowski join the Nexcella Board
of Directors. He is a proven finance and capital markets leader of
pharmaceutical organizations including Mylan and CareFusion,
successfully navigating complex situations throughout his
distinguished career, including Mylan N.V.’s interaction with Carl
Icahn and other activist investors,” said Ilya Rachman, MD, Ph.D.,
Chief Executive Officer of Immix Biopharma. Gabriel Morris,
Chief Financial Officer of Immix Biopharma, added, “Mr. Borkowski’s
deep capital markets and finance experience will be invaluable to
our team, especially as we advance our NXC-201 CAR-T program into
planned US clinical trials. We look forward to benefiting
from his valuable guidance.”
“I am delighted to join the Nexcella team and contribute my
knowledge and expertise to developing therapies that benefit
patients globally,” said Mr. Borkowski. “I look forward to working
with the Nexcella team on their pioneering cell therapy
programs.”
In addition to his service at Mylan and CareFusion, Mr.
Borkowski has served as a senior executive of a number of public
and private biopharmaceutical, medical device, and healthcare
companies in his career spanning over three decades, including:
Chief Financial Officer, ConvaTec; Chief Financial Officer,
Concordia Healthcare (now Advanz Pharma); and Chief Financial
Officer, Amerigen Pharmaceuticals, as well as having held senior
financial positions at American Home Products (Wyeth, now Pfizer).
Mr. Borkowski is a Trustee of Allegheny College. Mr.
Borkowski received his MBA in accounting from Rutgers University
subsequent to having earned his degree in Economics and Political
Science from Allegheny College.
About Nexcella, Inc.Nexcella, Inc., a
subsidiary of Immix Biopharma, Inc (Nasdaq:IMMX), is a Los Angeles,
CA based clinical-stage biopharmaceutical company engaged in the
discovery and development of novel cell therapies for oncology and
other indications. Our lead candidate, next generation
BCMA-targeted CAR-T NXC-201 for multiple myeloma and AL amyloidosis
has produced 92% and 100% response rates in each indication,
respectively, as of February 9, 2023 across 58 patients. We believe
NXC-201 has potential to be the world’s first outpatient CAR-T. Our
N-GENIUS platform allows us to discover, develop, and manufacture
cutting-edge cell therapies for patients in need. To learn more
about Nexcella, Inc. visit us at www.nexcella.com.
About Immix Biopharma, Inc.Immix Biopharma,
Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage
biopharmaceutical company pioneering a novel class of CAR-T cell
therapies and Tissue-Specific Therapeutics (TSTx) targeting
oncology and immuno-dysregulated diseases with >75 patients
treated to-date. Our lead cell therapy asset is NXC-201 in multiple
myeloma and AL Amyloidosis, which we believe could be the world’s
first out-patient CAR-T. Our lead TSTx asset IMX-110, currently in
Phase 1b/2a clinical trials as a monotherapy and IMMINENT-01
combination clinical trial with BeiGene’s anti-PD-1 antibody
tislelizumab, holds Orphan Drug Designation (ODD) and Rare
Pediatric Disease Designation (RPDD) by the FDA. ImmixBio
subsidiary Nexcella, Inc develops CAR-T NXC-201 for multiple
myeloma and AL amyloidosis, with 92% and 100% response rates in
each indication, respectively, as of February 9, 2023, currently
being trialed in NEXICART-1. Learn more at www.immixbio.com.
Forward Looking StatementsThis press release
contains “forward-looking statements” Forward-looking statements
reflect our current view about future events. When used in this
press release, the words “anticipate,” “believe,” “estimate,”
“expect,” “future,” “intend,” “plan,” or the negative of these
terms and similar expressions, as they relate to us or our
management, identify forward-looking statements. Such statements,
include, but are not limited to, statements contained in this press
release relating to our business strategy, our future operating
results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned including: the uncertainties related
to market conditions and other factors described more fully in the
section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report
on Form 10-K for the year ended December 31, 2022, and other
periodic reports filed with the Securities and Exchange Commission.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Immix Biopharma, Inc.
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Factors or events that could cause our actual results to differ
may emerge from time to time, and it is not possible for us to
predict all of them. We cannot guarantee future results, levels of
activity, performance or achievements.
ContactsStern Investor RelationsAlex
LoboManaging DirectorAlex.lobo@sternir.com
Company Contactirteam@immixbio.com
Immix Biopharma (NASDAQ:IMMX)
過去 株価チャート
から 5 2024 まで 6 2024
Immix Biopharma (NASDAQ:IMMX)
過去 株価チャート
から 6 2023 まで 6 2024